EKF Diagnostics (OTCMKTS:EKDHF – Get Free Report) will likely be releasing its results before the market opens on Tuesday, March 24th. Analysts expect EKF Diagnostics to post earnings of $0.0081 per share and revenue of $35.5660 million for the quarter.
EKF Diagnostics Price Performance
Shares of EKF Diagnostics stock opened at $0.34 on Tuesday. The stock has a 50 day moving average of $0.35 and a 200 day moving average of $1,512.68. EKF Diagnostics has a 12 month low of $0.24 and a 12 month high of $0.42.
About EKF Diagnostics
EKF Diagnostics Holdings plc (OTCMKTS: EKDHF) is a global in vitro diagnostics company that develops, manufactures and markets a broad range of point-of-care and laboratory analyzers, reagents and consumables. The company’s product portfolio addresses key segments of the diagnostic testing market, including haematology, biochemistry, immunoassay, haemostasis and diabetes monitoring.
EKF Diagnostics offers peripheral blood analyzers designed for use in clinical laboratories, hospitals and veterinary clinics, along with handheld and benchtop devices for rapid on-site testing.
See Also
- Five stocks we like better than EKF Diagnostics
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for EKF Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EKF Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
